CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... [Yahoo! Finance]
CytomX Therapeutics, Inc. (CTMX)
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytomx.com
Company Research
Source: Yahoo! Finance
Revenue: $33.4 million for the third quarter, up from $26.4 million in the third quarter of 2023. Operating Expenses: $29.3 million for the third quarter, an increase of $6.1 million compared to the third quarter of 2023. R&D Expenses: $21.4 million for the third quarter of 2024, an increase of $4.9 million compared to the corresponding quarter in 2023. G&A Expenses: $8 million for the third quarter, up from $6.8 million for the corresponding period in 2023. Pre-clinical Milestones: $10 million received year-to-date through collaboration with Ellis. Warning! GuruFocus has detected 7 Warning Signs with CTMX. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript CytomX Therapeutics Inc ( NASDAQ:CTMX ) has over 15 active discovery and development programs, with three currently in Phase 1 clinical development. The company reported positive Phase 1A dose escalation data for CX-904, showing a fa
Show less
Read more
Impact Snapshot
Event Time:
CTMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTMX alerts
High impacting CytomX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CTMX
News
- CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare ConferenceGlobeNewswire
- Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics, Inc. (NASDAQ: CTMX) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
CTMX
Earnings
- 11/7/24 - Beat
CTMX
Analyst Actions
- 11/11/24 - HC Wainwright
CTMX
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- CTMX's page on the SEC website